Big Basin Capital

Big Basin Capital is a cross-Pacific venture firm operating across Silicon Valley and Korea, with a focus on providing crucial early capital and US market entry support for sophisticated enterprise software and digital health companies. The firm sits in a relatively narrow strategic space: it backs companies that are either Korean by origin and intend to compete in the United States, or American companies that benefit from access to Korean enterprise customers and capital networks.

The Big Basin thesis emphasizes companies with strong technical foundations and clear potential for global commercial scale rather than those indexed to a single market. Within healthcare the firm concentrates on digital health, health IT, and biotech, with particular interest in AI-enabled software platforms and companies whose products serve enterprise healthcare customers like hospitals, payers, and pharma. The cross-border orientation means the firm is most interested in founders who are willing to build genuinely international companies from early stages rather than treating geographic expansion as a deferred problem.

Check sizes commonly fall in the 250 thousand to one million dollar range at entry, with the firm participating at pre-seed, seed, and selectively Series A. Geographic footprint is split between the United States and Korea, with the firm operating offices and partner presence in both markets. That structure is the firm’s defining feature; few early-stage venture firms can credibly support both Korean enterprise relationships and US commercial entry from a single partnership.

The team includes investment professionals with backgrounds in cross-border venture, operating roles at technology companies, and the Korean institutional investor ecosystem. Decision-making is reasonably efficient given the firm’s size, and the team is responsive to founders who can articulate a clear thesis on how the cross-border value creation will work in practice.

For founders, Big Basin Capital is most useful when the company’s growth genuinely depends on operating across the US and Korean markets rather than treating one as a future option. Useful introductions include Korean enterprise customers, Korean institutional and corporate investors for downstream rounds, US enterprise prospects through the Silicon Valley network, and selectively partners in the broader portfolio where commercial collaboration could accelerate growth. Post-investment engagement is collaborative and often hands-on at the early stages, particularly around US market entry strategy, hiring senior commercial leaders, and structuring partnership conversations with Korean institutions. Founders building purely for the US market or purely for the Korean market will find the firm’s value-add less differentiated than peers focused on a single geography. For enterprise health software, AI in healthcare, and digital health founders building cross-Pacific companies, Big Basin Capital is among the more deliberately positioned partners for that specific journey, and the firm’s ability to coordinate Korean and US activity across the same portfolio company is a real structural advantage rather than marketing.